Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The products of the Company include AVONEX, RITUXAN, TYSABRI and FUMADERM. The Company’s products address diseases, such as multiple sclerosis (MS), non-Hodgkin’s lymphoma (NHL), rheumatoid arthritis (RA), Crohn’s disease (CD) and psoriasis. In addition to the marketed products, Biogen Idec has a number of product candidates in or near registrational stage development. It includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon beta-1a. 

http://www.biogenidec.com/